



SAFETY DATA SHEET

Revision date: 16-May-2014

Version: 3.0

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Hydrocortisone Sodium Succinate for Injection (Act-O-Vial)

Trade Name: Solu-Cortef

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as anti-inflammatory

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 2

EU Classification:

EU Indication of danger: Toxic to Reproduction: Category 3

EU Risk Phrases:

R63 - Possible risk of harm to the unborn child.

Label Elements

Signal Word: Warning

Hazard Statements: H361d - Suspected of damaging the unborn child

Precautionary Statements:

P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection (Act-O-Vial)
Revision date: 16-May-2014

Page 2 of 9

Version: 3.0



Other Hazards No data available
Australian Hazard Classification (NOHSC): Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Hydrocortisone Sodium Succinate	125-04-2	204-725-5	Repr.Cat.3;R63	Repr. 2 (H361d)	< 86
Sodium hydroxide	1310-73-2	215-185-5	C; R35	Skin Corr. 1A (H314)	**
Benzyl Alcohol	100-51-6	202-859-9	Xn; R20/22	Acute Tox. 4 (H302) Acute Tox. 4 (H332)	<14

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Sodium phosphate, monobasic	7558-80-7	231-449-2	Not Listed	Not Listed	*
Sodium phosphate, dibasic	7558-79-4	231-448-7	Not Listed	Not Listed	*

Additional Information:

- * Proprietary
- ** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
 In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection (Act-O-Vial)
Revision date: 16-May-2014

Page 3 of 9

Version: 3.0

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Carbon dioxide, carbon monoxide

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. Avoid contact with eyes, skin and clothing. Avoid breathing dust. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): No data available

SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection (Act-O-Vial)
Revision date: 16-May-2014

Page 4 of 9

Version: 3.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Hydrocortisone Sodium Succinate

Pfizer OEL TWA-8 Hr: 100µg/m³, Skin

Sodium hydroxide

ACGIH Ceiling Threshold Limit:	2 mg/m ³
Australia PEAK	2 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Bulgaria OEL - TWA	2.0 mg/m ³
Czech Republic OEL - TWA	1 mg/m ³
Estonia OEL - TWA	1 mg/m ³
France OEL - TWA	2 mg/m ³
Greece OEL - TWA	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Japan - OELs - Ceilings	2 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
OSHA - Final PELs - TWAs:	2 mg/m ³
Poland OEL - TWA	0.5 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Switzerland OEL - TWAs	2 mg/m ³

Benzyl Alcohol

Bulgaria OEL - TWA	5.0 mg/m ³
Czech Republic OEL - TWA	40 mg/m ³
Finland OEL - TWA	10 ppm
	45 mg/m ³
Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Poland OEL - TWA	240 mg/m ³

Analytical Method:

Analytical method available for hydrocortisone. Contact Pfizer Inc for further information.

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection (Act-O-Vial)
Revision date: 16-May-2014

Page 5 of 9

Version: 3.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Powder plus sterile diluent	Color:	White to off-white
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
Solubility:	Soluble: Water		
pH:	7-8 (solution)		
Melting/Freezing Point (°C):	No data available		
Boiling Point (°C):	No data available.		
Partition Coefficient: (Method, pH, Endpoint, Value)			
Sodium phosphate, dibasic			
No data available			
Sodium phosphate, monobasic			
No data available			
Sodium hydroxide			
No data available			
Hydrocortisone Sodium Succinate			
No data available			
Benzyl Alcohol			
No data available			
Decomposition Temperature (°C):	No data available.		
Evaporation Rate (Gram/s):	No data available		
Vapor Pressure (kPa):	No data available		
Vapor Density (g/ml):	No data available		
Relative Density:	No data available		
Viscosity:	No data available		
Flammability:			
Autoignition Temperature (Solid) (°C):		No data available	
Flammability (Solids):		No data available	
Flash Point (Liquid) (°C):		No data available	
Upper Explosive Limits (Liquid) (% by Vol.):		No data available	
Lower Explosive Limits (Liquid) (% by Vol.):		No data available	

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under recommended storage conditions. Solutions are unstable after 4 hours.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection (Act-O-Vial)
Revision date: 16-May-2014

Page 6 of 9

Version: 3.0

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May cause eye, skin and respiratory tract irritation (based on components) . May be absorbed through the skin in harmful amounts. Central nervous system effects such as headache, dizziness, drowsiness, fatigue, and lack of muscular coordination can also occur. May cause stomach irritation, diarrhea, nausea, or vomiting.

Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects: Effects on vision have been seen during clinical use. Drugs of this class may cause Cushing's syndrome, manifested by moon face, obesity, headache, acne, thirst, increased urination, impotence, menstrual irregularities, facial hair growth, and mental changes. Clinical use may cause an increase in blood pressure (hypertension). Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Hydrocortisone Sodium Succinate

Rat Oral LD 50 5000 mg/kg

Mouse Oral LD 50 5000mg/kg

Rat Subcutaneous LD 50 449mg/kg

Mouse Subcutaneous LD 50 >500mg/kg

Rat Intraperitoneal LD 50 150mg/kg

Benzyl Alcohol

Rat Oral LD50 1230 mg/kg

Rat Para-periosteal LD50 53mg/kg

Rat Inhalation LC50 >4.178mg/L

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

Hydrocortisone Sodium Succinate

Eye Irritation Rabbit Minimal

Benzyl Alcohol

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Moderate

Skin Irritation Guinea Pig Moderate

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Hydrocortisone Sodium Succinate

7 Day(s) Mouse Oral 140 mg/kg/day LOAEL Thymus

4 Day(s) Mouse Subcutaneous 100 mg/kg/day LOAEL Liver

SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection (Act-O-Vial)

Revision date: 16-May-2014

Page 7 of 9

Version: 3.0

11. TOXICOLOGICAL INFORMATION

11 Day(s)	Mouse	Subcutaneous	62 mg/kg/day	LOAEL	Endocrine system
2 Week(s)	Mouse	Subcutaneous	560 mg/kg/day	LOAEL	Liver, Bone Marrow
85 Day(s)	Rat	Subcutaneous	175 mg/kg/day	LOAEL	Adrenal gland

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Hydrocortisone Sodium Succinate

Reproductive & Fertility-Females	Rat	Oral	210 mg/kg/day	LOAEL	Maternal toxicity
Embryo / Fetal Development	Mouse	Oral	10 mg/kg/day	LOAEL	Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Hydrocortisone Sodium Succinate

Bacterial Mutagenicity (Ames)	<i>Salmonella</i>	Negative
<i>In Vivo In Vitro</i> Direct DNA Damage	Rat , Mouse	Positive
<i>In Vivo In Vitro</i> Chromosome Aberration	Rat , Mouse	Positive
Cytogenetics	Mouse	Negative

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:	Environmental properties of the formulation have not been thoroughly investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:	Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.
---------------------------------	---

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

HYDROCORTISONE SODIUM SUCCINATE FOR INJECTION

SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection (Act-O-Vial)
Revision date: 16-May-2014

Page 8 of 9

Version: 3.0

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Hydrocortisone Sodium Succinate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	204-725-5

Sodium hydroxide

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	215-185-5

Benzyl Alcohol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-859-9

Sodium phosphate, monobasic

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-449-2

Sodium phosphate, dibasic

SAFETY DATA SHEET

Material Name: Hydrocortisone Sodium Succinate for Injection (Act-O-Vial)
Revision date: 16-May-2014

Page 9 of 9

Version: 3.0

15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb
California Proposition 65	2270 kg
Inventory - United States TSCA - Sect. 8(b)	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Present
	231-448-7

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child
Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage
Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled

Toxic to Reproduction: Category 3

C - Corrosive

Xn - Harmful

R35 - Causes severe burns.

R63 - Possible risk of harm to the unborn child.

R20/22 - Harmful by inhalation and if swallowed.

Data Sources: Safety data sheets for individual ingredients. Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 13 - Disposal Considerations. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information.

Revision date: 16-May-2014

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet